The Oncolytic Virus Therapy Market is witnessing rapid development as researchers and pharmaceutical companies explore innovative approaches to cancer treatment. WiseGuyReports projects that the global market will grow from USD 3.0 billion in 2025 to USD 9.8 billion by 2035, expanding at a CAGR of approximately 12.4%.

One of the major trends shaping the market is the integration of oncolytic viruses with existing cancer therapies. Combination approaches involving immunotherapy and chemotherapy are attracting increasing research interest because they may improve therapeutic effectiveness and patient outcomes. The growing emphasis on personalized medicine is another important opportunity for the industry.

Genetic engineering and viral manipulation technologies are enabling researchers to develop viruses with improved tumor selectivity and therapeutic performance. Advanced gene-editing technologies, including CRISPR-based approaches, may further support innovation in this field.

The market is categorized into applications such as melanoma, colorectal cancer, breast cancer, and lung cancer. It is also segmented by viruses, oncolytic virotherapy, and gene therapy. Hospitals, cancer research institutes, and outpatient clinics represent key end users.

North America currently holds a strong position due to healthcare infrastructure and research funding, while Europe benefits from clinical research and regulatory support. Asia-Pacific is also emerging as an attractive market because of rising cancer incidence and expanding healthcare access.

Increasing research investments, biotechnology collaborations, and advancements in viral engineering are expected to create substantial opportunities for market participants.